KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
Dent R, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Jia L, Jensen E, Karantza V, Aktan G, O'Shaughnessy J, Schmid P (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S1241-S1242
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2020.10.021
Authors with CRIS profile
Involved external institutions
Karolinska Institute
Sweden (SE)
Philipps-Universität Marburg
Germany (DE)
National University of Singapore (NUS)
Singapore (SG)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)
United States (USA) (US)
Cedars-Sinai Medical Center
United States (USA) (US)
Yale University
United States (USA) (US)
Champalimaud Foundation / Fundação Champalimaud
Portugal (PT)
Queen Mary University of London
United Kingdom (GB)
Westmead Hospital
Australia (AU)
Baylor University (BU)
United States (USA) (US)
Kliniken Essen-Mitte
Germany (DE)
Sungkyunkwan University (SKKU)
Korea, Republic of (KR)
IOB Institute of Oncology
Spain (ES)
Sweden (SE)
Philipps-Universität Marburg
Germany (DE)
National University of Singapore (NUS)
Singapore (SG)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)
United States (USA) (US)
Cedars-Sinai Medical Center
United States (USA) (US)
Yale University
United States (USA) (US)
Champalimaud Foundation / Fundação Champalimaud
Portugal (PT)
Queen Mary University of London
United Kingdom (GB)
Westmead Hospital
Australia (AU)
Baylor University (BU)
United States (USA) (US)
Kliniken Essen-Mitte
Germany (DE)
Sungkyunkwan University (SKKU)
Korea, Republic of (KR)
IOB Institute of Oncology
Spain (ES)
How to cite
APA:
Dent, R., Cortes, J., Pusztai, L., Mcarthur, H.L., Kuemmel, S., Bergh, J.,... Schmid, P. (2020). KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC). In ANNALS OF ONCOLOGY (pp. S1241-S1242). AMSTERDAM: ELSEVIER.
MLA:
Dent, R., et al. "KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)." Proceedings of the ESMO Asia Virtual Congress AMSTERDAM: ELSEVIER, 2020. S1241-S1242.
BibTeX: Download